

Table 1. Clinical characteristics at baseline parameters and of all subjects

Group	Control group (n=28)	Fenofibrate group (n=28)	<i>P</i>
Sex (male/%)	17/60.7	20/71.4	0.604
Age (year)	56.03 ± 12.32	54.64 ± 10.09	0.593
Duration of diabetes (years)	5.21 ± 2.02	5.83 ± 1.39	0.716
Hypertension (number/%)	10/35.7	11/39.3	0.500
AECI/ARB (number/%)	7/25.0	8/28.6	0.768
CCB (number/%)	5/17.9	5/17.9	0.636
Metformin (number/%)	15, 53.6	13, 46.4	0.601
α-Glucosidase inhibitors (number/%)	20, 71.42	22, 78.6	0.546
Sulfonylureas (number/%)	12, 42.9	11, 39.3	0.791
Glinides (number/%)	10, 35.7	11, 39.3	0.787
Insulin (number/%)	6, 21.4	8, 28.6	0.786
Insulin/Oral medications (%)	22.2	28.6	0.372
Simvastatin (number/%)	12/42.9	10/35.7	0.392
Atorvastatin (number/%)	9/28.0	12/42.9	0.291
Rosuvastatin (number/%)	3/10.7	2/7.1	0.500
pravastatin(number/%)	4/14.3	6/21.4	0.364
SBP (mmHg)	137.75 ± 13.77	137.71 ± 9.59	0.996
DBP (mmHg)	75.00 ± 5.60	76.29 ± 7.87	0.782

BMI, kg/m ²	27.28 ± 3.99	28.32 ± 4.36	0.429
FPG, mmol/L	7.92 ± 2.16	8.27 ± 1.31	0.606
HbA1c, %	7.62 ± 0.87	7.48 ± 0.86	0.480
TG, mmol/L	2.41(2.13,3,31)	2.79 (2.12, 3.76)	0.606
TC, mmol/L	4.59 ± 1.14	4.79 ± 1.01	0.474
LDL-C, mmol/L	2.47 ± 0.90	2.55 ± 0.94	0.670
HDL-C, mmol/L	1.02 ± 0.20	1.09 ± 0.24	0.275
Scr, μmol/L	69.56 ± 15.43	65.46 ± 20.98	0.349
UA, μmol/L	388.44 ± 126.99	372.46 ± 72.78	0.803
UACR, mg/g	105.00(64.00, 165.00)	129.00 (53.00, 226.25)	0.095
eGFR ml/min/1.73m ²	94.01 (80.95, 120.95)	105.36 (99.68, 116.92)	0.066
FINS, μIU/mL	12.9 (6.75, 15.78)	12.05 (8.35, 14.95)	0.101
HOMA-IR	4.50 (3.13, 5.95)	4.27 (3.05, 5.35)	0.105
HOMA-β	42.04 (25.33, 75.23)	49.51 [35.85, 70.05]	0.127

Data are means ± SD or medians (interquartile range) or n (%).

AECI/ARB: Angiotensin Converting Enzyme Inhibitors/Angiotensin receptor antagonist; CCB: Ca-Antagonists; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FBG: fasting blood glucose; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; Scr: serum creatinine; UA: uric acid; UACR: urinary albumin creatinine ratio; eGFR: estimated glomerular filtration rate; FINS: fasting serum insulin; HOMA-IR: homeostasis model assessment for insulin resistance, HOMA-β: homeostasis model assessment for β-cell function.

Table 2. The changes of Clinical characteristics after 90 and 180 days follow up

Group	Control (n=28)	Fenofibrate treatment (n=28)
SBP (mmHg)		
90 days	-2.00(-7.00,3.00)	-1.00(-3.00, -1.00)
180 days	-2.50(-8.00, 5.00)	-1.00(-7.00, 4.00)
DBP (mmHg)		
90 days	-0.80(-3.00, 4.00)	-1.00(-3.00, -1.00)
180 days	-1.00(-2.00, 5.00)	-1.20(-2.00, 0.25)
BMI, kg/m ²		
90 days	-0.26(-1.56,0.12)	-0.20(-1.16,0.15)
180 days	-0.22(-1.32,0.17)	-0.21(-1.01,0.22)
FPG, mmol/L		
90 days	-0.43(-1.70,0.50)	-0.37(-1.77, 0.32)
180 days	-0.24(-2.44, 0.39)	-0.68(-2.81,0.19)
HbA1c, %		
90 days	-0.60(-1.30,0.10)	-0.40(-1.35, -0.10)
180 days	-0.90(-1.40, -0.25)	-0.70(-1.38, -0.10)
TG, mmol/L		
90 days	-0.64(-0.96,0.42)	-1.27(-1.77, -0.24) *
180 days	-0.22(-1.21,0.19)	-1.91(-1.12, -0.53) #
TC, mmol/L		

90 days	-0.19(-1.26,0.11)	-0.19(-0.77, -0.19)
180 days	0.22(-0.29, 0.53)	-0.21 (-0.87,0.31)
LDL-C, mmol/L		
90 days	-0.10(-0.80,0.10)	-0.15(-0.50, 0.72)
180 days	0.25(-0.18, 0.40)	-0.20(-0.40,0.40)
HDL-C, mmol/L		
90 days	0.00(0.00,0.01)	0.20(0.10,0.20) *
180 days	0.00(0.00,0.01)	0.16(0.00,0.22) *
Scr, $\mu\text{mol/L}$		
90 days	1.70(-2.40,5.20)	7.60(3.80, 12.40) *
180 days	4.35(-0.95, 9.80)	4.25 (-1.75, 15.60)
UA, $\mu\text{mol/L}$		
90 days	0.00(-60.00,45.00)	-92.5(-145, -21) *
180 days	-16.00(-43.75, -16.00)	-66(-111.00, -34.00) *
UACR, mg/g		
90 days	-20.87(-61.16,15.72)	-41.39(-103.81, -1.44)
180 days	-8.15(-59.69, 41.94)	-44.05(-179.47, -12.16) #
<hr/>		
eGFR ml/min/1.73m ²		
90 days	-2.27(-7.33,4.63)	-9.25(-22.10, -8.28) *
180 days	-5.63(-12.10,1.12)	-7.26(-21.34, -1.37)

FINS, $\mu\text{IU/mL}$		
90 days	-0.60(-3.45,2.12)	-0.90(-4.50,2.10)
180 days	-0.25(-5.15, 2.35)	-1.40(-6.90, 1.81)
HOMA-IR		
90 days	-0.35(-1.98,0.64)	-0.25(-2.77, 0.45)
180 days	-1.09(-2.68, -1.09)	-0.94(-3.15, 0.58)
HOMA- β		
90 days	6.19(-38.88, 20.64)	3.62(-6.21,25.04)
180 days	6.98(-39.58, 34.25)	4.75(-21.91, 30.38)

Data are means \pm SD or medians (interquartile range) or n (%).

AECI/ARB: Angiotensin Converting Enzyme Inhibitors/Angiotensin receptor antagonist; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FBG: fasting blood glucose; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; Scr: serum creatinine; UA: uric acid; UACR: urinary albumin to creatinine ratio; eGFR: estimated glomerular filtration rate; FINS: fasting serum insulin; HOMA-IR: homeostasis model assessment for insulin resistance, HOMA- β : homeostasis model assessment for β -cell function.

*** $P < 0.05$ vs. the 90 days of control group. # $P < 0.05$ vs. the 180 days of control group.**